Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Serum IFN-γ levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis

Fig. 1

Trail profile. 105 rheumatoid arthritis (RA) patients were enrolled and randomized allocated into two groups. 12 weeks after MSCT, outcomes of the MSCT group patients were evaluated according to the EULAR response criteria, taking into consideration of both current DAS28 value and its reduction after treatment, those with good or moderate response were put into the response group (n = 28), and those with no response were put into the no-response group (n = 24). Most enrolled patients completed 48 weeks follow-up, but there are 2 of the no-response group and 5 of the control group lost to follow-up. MSCT, mesenchymal stem cell transplantation. DAS28, the 28-joint disease activity score

Back to article page